For the third quarter of 2024, the Company reported a net loss attributable to common stockholders of $4.9 million, or $5.79 per share, compared to $7.9 million, or $14.20 per share in the third ...
When completed, AV001 will be the first blinded randomized controlled trial in post-surgical neuropathic pain that evaluates the long term treatment effects of a topical neuropathic pain treatment.
The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...
The studies highlighted in the publication, titled " An in vitro and in vivo efficacy evaluation of a novel gene therapy candidate (SBT101) in mouse models of adrenomyeloneuropathy and in NHPs ,” ...